MedPath

Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol

Phase 4
Conditions
Hyperalgesia
Interventions
Drug: Saline
Registration Number
NCT02934763
Lead Sponsor
Pontificia Universidad Catolica de Chile
Brief Summary

Opioid Induced Hyperalgesia (OIH) is an entity than has been demonstrated in healthy volunteers and in animal models. Is defined as an increase in the perception to painful stimuli, increasing the opioid requirements and diminishing the pain thresholds to stimuli.

The apparition of OIH is also related to the exposure to opioids during surgery, depending of the dose, the time of exposition and the type of opioid.

This condition can be modulated, specially in the perioperative context. It has been seen in healthy volunteers and in animal models, than the use of propranolol can modulate this phenomena, diminishing the postoperative requirements of analgesia. It is also unknown, the dose of propranolol required to modulate adequately OIH.

The objective of this work is to evaluate the efficacy of propranolol in the modulation of opioid induced hyperalgesia, with lower postoperative requirements of analgesia rescue.

Detailed Description

This is a randomized controlled study, comparing 2 interventions with a placebo. The interventions will be use of propranolol, at different doses, to achieve specific plasmatic concentrations.

80 patients will be required to find a difference of 20% in the primary outcome.

The primary outcome to be measured is the postoperative use of opioids in the post anesthesic care unit.

Secondary outcomes, will be the amount of opioids used in the following 24 hours to the surgery, the time to the first dose of analgesia in the post anesthesic care unit, and the change in the pain thresholds, evaluated as pain by pressure and by tactile sensitivity, before and after surgery.

Also, as a secondary outcome, in a group than will not receive the study drug, we will evaluate the temporal changes in opioid induced hyperalgesia, by pain sensitivity measured in the postoperative hours 2, 4 and 24. 10 patients receiving placebo will be part of this additional measures.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients scheduled for elective laparoscopic cholecystectomy
  • American Society of Anesthesiology Score (ASA) I-II
Exclusion Criteria
  • Medical history of cardiac disease
  • Medical history of respiratory disease
  • Regular use of beta blockers
  • Known allergies to drugs used in the study
  • Known history of illicit drugs use

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboSalineSaline solution by target controlled infusion
Propranolol at 5ng/ml target dosePropranololPropranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
Propranolol at 15ng/ml target dosePropranololPropranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
Primary Outcome Measures
NameTimeMethod
Postoperative opioid use24 hours posterior to surgery

Dose of opioid required to manage pain adequately

Secondary Outcome Measures
NameTimeMethod
Pain thresholds (cold)24 hours posterior to surgery

Evaluation of the threshold to perceive a cold perception as pain

Pain thresholds (heat)24 hours posterior to surgery

Evaluation of the threshold to perceive a heat perception as pain

Temporal changes in pain sensibility24 hours posterior to surgery

Evaluation of pain by tactile sensitivity, using the PinPrick system

Pain thresholds (tactile sensitivity)24 hours posterior to surgery

Evaluation of pain by tactile sensitivity, using the PinPrick system

© Copyright 2025. All Rights Reserved by MedPath